Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

TKP (3479): Slow Recovery yet Share Price Has More than Doubled?

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

  TKP Corporation  / Equity Capital Markets

<p>TKP (3479 JP) announced an additional offering early today. The company plans to raise up to USD 209 million to fund its acquisition of Regus Japan. In this insight, we will provide our thoughts on the deal and score the deal in our ECM Framework. We like the company's fundamentals as a leading shared business facility operator in Japan. The acquisition of Regus Japan helps consolidate the company's market leadership in Japan. </p>

TKP (3479 JP) announced an additional offering early today. The company plans to raise up to USD 209 million to fund its acquisition of Regus Japan. In this insight, we will provide our thoughts on the deal and score the deal in our ECM Framework. We like the company's fundamentals as a leading shared business facility operator in Japan. The acquisition of Regus Japan helps consolidate the company's market leadership in Japan. 

TKP Placement: The We-Work Competitor with Rapid Growth